Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01949766
Expanded Access Status : No longer available
First Posted : September 24, 2013
Last Update Posted : September 24, 2013
Information provided by (Responsible Party):
University of Pittsburgh

Brief Summary:
This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

Condition or disease Intervention/treatment
Byler Disease Drug: Glycerol phenylbutyrate

Layout table for study information
Study Type : Expanded Access
Official Title: Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

Intervention Details:
  • Drug: Glycerol phenylbutyrate
    Other Name: RAVICTI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Byler Disease
  • Cholestasis
  • Tolerance of Buphenyl therapy

Exclusion Criteria:

  • Allergy/Hypersensitivity to RAVICTI

No Contacts or Locations Provided

Layout table for additonal information
Responsible Party: University of Pittsburgh Identifier: NCT01949766    
Other Study ID Numbers: PRO12070385.2
First Posted: September 24, 2013    Key Record Dates
Last Update Posted: September 24, 2013
Last Verified: September 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholestasis, Intrahepatic
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Liver Diseases
4-phenylbutyric acid
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents